Experience the future
of pathology

Our Story

Since 2016, Ibex has led the way in AI-powered diagnostics for pathology.
We set out to transform pathology by ensuring that every patient can receive an accurate, timely and personalized cancer diagnosis.
Today, we are the most widely-deployed artificial intelligence platform in pathology. Developed by pathologists for pathologists, our solutions
serve the world’s leading physicians, healthcare organizations and diagnostic providers.
Every day, we have the privilege of touching the lives of patients worldwide. We raise physician confidence, streamline diagnostic workflows,
help clinicians provide more personalized diagnosis and, most importantly, enable better clinical outcomes.

Field-proven AI solution

Deployed worldwide, detecting breast, prostate and gastric cancer in multiple workflows

Better clinical outcomes

Enhanced diagnostic quality. Faster turnaround. Greater confidence

AI-powered pathology

Unprecedented insights and predictions, at the speed of technology


Joseph Mossel

Co-founder & CEO

Chaim Linhart, PhD

Co-founder & CTO

Judith Sandbank, MD

Chief Medical Officer

Yair Heller

Chief Operating Officer

Stuart Shand

Chief Commercial Officer

Dalit Kahana Garbi

Chief Legal Officer

Kimberly Gasuad

SVP, Business Development & Strategy

Michal Shoval

SVP Human Resources

Advisory Board

David Shulkin, MD


Mahul B. Amin, MD

University of Tennessee Health Science Center

Liron Pantanowitz, MD

University of Pittsburgh Medical Center

Anne Vincent-Salomon, MD

Institut Curie

Stuart Schnitt, MD

Brigham and Women's Hospital

Gregory Lauwers, MD

Moffitt Cancer Center

Sylvia L. Asa, MD, PhD

University Hospitals Cleveland Medical Center

Ajit Singh, PhD

Artiman Ventures
Stanford University

Joe Robinson


Yair Briman


Board of Directors

Michael Lewin

Chairman of the Board

Chris Hillock

Board Member

Joseph Mossel

Board Member & CEO

Chaim Linhart, PhD

Board Member & CTO

Roy Wiesner

Board Member

Gil Goren

Board Member

Ann Costello

Board Member

Our Investors